Back to search

Article

A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers

2022-07-03

Abstract excerpt

<h4>ABSTRACT</h4> Immune checkpoint blockade impedes the negative regulatory signals for T-cell response and permits more effective immune detection and eradication of cancer cells. This single-arm phase II clinical trial (ACTRN12616001019493) within the Molecular Screening and Therapeutics (MoST) program evaluates the clinical activity and safety of combination immunotherapy with durvalumab and tremelimumab in p...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2a4cfbcb-0df4-548a-b9f4-4f9cc38954ea
DOI
10.1101/2022.06.30.22277092
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common CancersDOI 10.1101/2022.06.30.22277092
Exploring the impact of Durvalumab on biliary tract cancer- insights from real world clinical dataSemantic proximity
Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancerSemantic proximity
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutationsSemantic proximity
Biomarker study of pembrolizumab in patients with advanced rare cancers.Semantic proximity
Prediction of pan-solid tumor pembrolizumab benefit by integrating tumor mutation and gene expression profilingSemantic proximity
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumabSemantic proximity
Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab.Semantic proximity
Market watch: emerging companion diagnostics for cancer drugs.Semantic proximity
FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer PatientsSemantic proximity
Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types.Semantic proximity
Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours.Semantic proximity
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONOSemantic proximity
Select a neighboring publication to make it the new centre.